CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy. (Q51887634)

16 April 2018

title

CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy. (English)

1 reference

16 April 2018

1 reference

Valeria Frangione

1

1 reference

16 April 2018

Lorenzo Mortara

2

1 reference

16 April 2018

Patrizia Castellani

3

1 reference

16 April 2018

Andrea De Lerma Barbaro

4

1 reference

16 April 2018

Roberto S Accolla

5

1 reference

16 April 2018

language of work or name

English

0 references

publication date

1 October 2010

1 reference

16 April 2018

International Journal of Cancer

published in

1 reference

16 April 2018

volume

127

1 reference

16 April 2018

issue

7

1 reference

16 April 2018

page(s)

1614-1624

1 reference

16 April 2018

The three Es of cancer immunoediting

cites work

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

21 January 2018

1 reference

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

Adoptive immunotherapy of cancer using CD4(+) T cells

21 January 2018

1 reference

Multiple roles for CD4+ T cells in anti-tumor immune responses

21 January 2018

1 reference

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

21 January 2018

1 reference

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

21 January 2018

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression

21 January 2018

1 reference

Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)

21 January 2018

1 reference

Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.

21 January 2018

1 reference

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.

21 January 2018

1 reference

Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions

21 January 2018

1 reference

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

21 January 2018

1 reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells

21 January 2018

1 reference

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product

21 January 2018

1 reference

Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.

21 January 2018

1 reference

Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.

21 January 2018

1 reference

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

21 January 2018

1 reference

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

21 January 2018

1 reference

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

CD4 cells can be more efficient at tumor rejection than CD8 cells

21 January 2018

1 reference

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice

21 January 2018

1 reference

IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.25183

1 reference

16 April 2018

1 reference

16 April 2018